XRTX XRTX
Company Profile ↓Company Overview
XRTX (XRTX) is a publicly traded company listed on with a market capitalization of $2.62M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -55.24% |
| 6 Months: | -8.29% |
| 3 Months: | -14.16% |
| 1 Month: | -12.76% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 65.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 963.46K | 889.95K | 716.20K | 686.42K | 823.30K |
| Operating Income | -963.46K | -889.95K | -716.20K | -686.42K | -823.30K |
| EBITDA | -937.47K | -862.32K | -686.81K | -657.30K | -797.45K |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -698.67K | -717.70K | -649.47K | -590.46K | -808.47K |
| Tax Provision | - | - | - | - | - |
| Net Income | -698.67K | -717.70K | -649.47K | -590.46K | -808.47K |
| Diluted EPS | -0.93 | -0.95 | -0.65 | - | -0.58 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 10.29M | 6.05M | 4.12M | 3.26M |
| Operating Income | - | -10.29M | -6.05M | -4.12M | -3.26M |
| EBITDA | - | -10.23M | -5.91M | -4.00M | -3.14M |
| Interest Expense | 4.39K | 0 | - | - | - |
| Pretax Income | - | -7.72M | -2.16M | -3.31M | -2.66M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -7.72M | -2.16M | -3.31M | -2.66M |
| Diluted EPS | - | -23.54 | -5.45 | -5.75 | -2.80 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 12.37M | 5.47M | 4.09M | 2.68M |
| Current Assets | - | 10.90M | 4.07M | 2.68M | 1.26M |
| Cash & Equivalents | - | 10.43M | 3.45M | 2.47M | 864.51K |
| Inventory | - | - | - | - | - |
| Receivables | - | 81.75K | 60.71K | 17.64K | 80.17K |
| Total Liabilities | - | 5.38M | 825.94K | 757.99K | 599.07K |
| Current Liabilities | - | 1.51M | 825.94K | 757.99K | 599.07K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 77.60K | 11.51K | 38.78K | 37.29K |
| Total Equity | - | 7.00M | 4.64M | 3.34M | 2.08M |
| Shares Outstanding | - | 334.01K | 399.77K | 696.27K | 1.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.17M | -6.58M | -3.68M | -2.77M |
| Investing Cash Flow | - | -45.70K | -46.36K | -38.92K | -294.95K |
| Financing Cash Flow | - | 3.91M | -361.04K | 2.78M | 1.43M |
| Capital Expenditure | - | -45.70K | -46.36K | -38.92K | -55.22K |
| Free Cash Flow | - | -8.21M | -6.63M | -3.72M | -2.82M |
| Net Change in Cash | - | -4.30M | -6.99M | -938.06K | -1.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -110.3% | -46.5% | -99.3% | -127.4% |
| ROCE % | - | -94.7% | -130.2% | -123.4% | -156.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 1.27% | 23.12K | $54.05K |
| 2 | Stonex Group Inc. | 0.90% | 16.37K | $38.27K |
| 3 | Royal Bank of Canada | 0.04% | 732 | $1.71K |
| 4 | National Bank of Canada/FI/ | 0.01% | 162 | $378 |
| 5 | TD Waterhouse Canada Inc. | - | 9 | $21 |
| 6 | Clearstead Advisors, LLC | - | 55 | $128 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XRTX
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORT…
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged…
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to t…
XORTX Announces Director Resignation
CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to …
XORTX Appoints New Director
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to …
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to …
XRTX — Frequently Asked Questions
What is the current share price of XRTX?
As of 2026-09-16 18:39 PDT, XRTX trades at $1.88 on NASDAQ/NYSE. Its 52-week range is $1.72 to $5.50.
What is the market capitalisation of XRTX?
XRTX has a market capitalisation of $2.62M on NASDAQ/NYSE.
What is the P/E ratio of XRTX?
XRTX trades at a trailing price-to-earnings (P/E) ratio of -0.67. Its price-to-book (P/B) ratio is 1.42.
What is the return on equity (ROE) of XRTX?
XRTX has a return on equity (ROE) of -127.43%.
Is XRTX a good stock to buy?
This page provides a data-driven analysis of XRTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.